Pathline launches new RapidPath™ Myeloid NGS  READ MORE

NextGen Sequencing Acute Myeloid Leukemia (AML) Panel (Major)

Alias/Synonym: NGS AML Major

CPT Code: 81445

Includes:
ASXL1, DNMT3A, FLT3, IDH1, IDH2, KIT, KRAS, NPM1, NRAS, RUNX1, SF3B1, TET2, TP53, U2AF1, WT1
Specimen Type, Preferred:
Bone marrow aspirate
Specimen Type, Alternate:
Sample Quantity, Preferred:
2mL
Sample Quantity, Minimum:
0.5mL
Transport Container:
Lavender top (EDTA) tube
Green top (Sodium Heparin) tube
Transport Temperature:
Refrigerated
Collection Instructions:
If bone marrow is dry tap, submit 5-10mL peripheral blood.
Specimen Stability:
Room temperature: 2 day(s)
Refrigerated: 3 day(s)
Rejection Criteria:
Room temperature Frozen
Clotted
Clinical Significance:
Detects mutations of clinical significance related to Acute Myeloid Leukemia (AML).
Limitations:
This test is designed to detect gene mutations only. It is not intended to detect copy number changes or gene rearrangements.
Turnaround Time:
10-14 day(s)
Reference Ranges:
Cutoff value % based on assay sensitivity